FDA Reviewer Not Sold on Increased Restrictions for Hydrocodone Combos

The FDA appears poised to oppose a Drug Enforcement Administration (DEA) proposal to place increased restrictions on hydrocodone-containing drug combination products. DEA is weighing whether to up-schedule the painkillers from Schedule III to Schedule II, but must first receive an evaluation and recommendation from the FDA.
Drug Industry Daily